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Abstract
Background: Poor initial response to tamoxifen due to CYP2D6 polymorphism and adverse side effects are two
clinical challenges in tamoxifen therapy. We report the development and preclinical testing of a boronic prodrug to
orally deliver 4-OHT at therapeutically effective concentrations but at a fraction of the standard tamoxifen dose.
Methods: A mouse xenograft tumor model was used to investigate the efficacy of ZB497 in comparison with
tamoxifen. Pharmacokinetic studies were conducted to evaluate the metabolism and bioavailability of the drug in
mice. Drug and metabolites distribution in xenograft tumor tissues was determined by high performance liquid
chromatography-tandem mass spectrometry.
Results: The boronic prodrug, ZB497, can not only be efficiently converted to 4-OHT in mice, but also afforded
over 30 fold higher plasma concentrations of 4-OHT than in mice given either the same dose of 4-OHT or
tamoxifen. Further, ZB497 was more effective than tamoxifen at lowered dosage in inhibiting the growth of
xenograft tumors in mice. Consistent with these observations, ZB497 treated mice accumulated over 6 times higher
total drug concentrations than tamoxifen treated mice.
Conclusions: Our study demonstrates that ZB497 effectively delivers a markedly increased plasma concentration
of 4-OHT in mice. The boronic prodrug was shown to have far superior bioavailability of 4-OHT compared to
tamoxifen or 4-OHT administration as measured by the area under the plasma concentration time curve (AUC),
plasma peak concentrations, and drug accumulation in tumor tissues. Further, ZB497 proves to be a more
efficacious hormone therapy than tamoxifen administered at a reduced dose in mice.
Background
Tamoxifen remains a safe and effective agent for women
diagnosed with ER (+) breast cancer. It is a first-line
agent for pre-menopausal breast cancer patients and for
women requiring secondary chemoprevention after a
DCIS or LCIS diagnosis. It is an option for other ER+
breast cancer patients who do not tolerate the side effects
of aromatase inhibitors. Results of the ATLAS trial show
that 10-years treatment with tamoxifen further improves
long-term survival compared to 5-years treatment [1].
However, the response to tamoxifen shows well-known in-
dividual variability [2–8]. Tamoxifen is a pro-drug, which
needs to be converted into active metabolites for optimal
clinical activity. Cytochrome P450 enzyme CYP2D6 is
required to convert tamoxifen into 4-hydroxytamoxifen
(4-OHT) and endoxifen [9], both of which are about 100
times more potent than tamoxifen [10, 11]. Genetic poly-
morphism in CYP2D6 affects the rate of metabolic activa-
tion of tamoxifen. This may account for poor initial
response to tamoxifen and worse disease outcome after
standard therapy. Multiple clinical studies have shown
that poor metabolizer (PM) patients tend to have shorter
overall survival rate than those who are extensive metabo-
lizers (EM) [4–8]. Existing clinical and laboratory data
support the hypothesis that bioavailable 4-OHT or
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endoxifen could offer improved therapeutic efficacy and
potentially lower dose requirements, with reduced adverse
effects [12–14]. Indeed, 4-OHT is being developed as a
topically applied gel currently in Phase II clinical trials
[15–18]. The use of orally available 4-OHT is hampered
by its rapid first-pass clearance due to O-glucuronidation
[19] and the resulting poor bioavailability compared to
oral tamoxifen. Clinical trials utilizing high-dose tamoxi-
fen have been conducted in PM patients in order to in-
crease blood levels of active metabolites. However, this
also increases the risk with adverse effects including hot
flashes and thrombosis [20].
We have recently developed several boron-derived pro-
drugs of 4-OHT that demonstrated potent antiestrogenic
activities in vitro at significantly lower concentrations than
tamoxifen [21]. We propose a novel endocrine therapy
regimen using ZB497, an orally bioavailable prodrug form
of 4-OHT that can be administered at lower doses than
standard tamoxifen treatment, thereby not only circum-
venting the need for CYP2D6 enzyme to catalyze the
hydroxylation of tamoxifen or N-desmethyltamoxifen, but
also potentially reducing or eliminating side effects by
virtue of significantly reduced dosage. In order to further
evaluate the prodrug as a potential new option in breast
cancer treatment and/or prevention, we conducted in vivo
efficacy studies using a well-characterized mouse xeno-
graft model based on the ERα positive MCF-7 breast
cancer cells. We determined whether the boron-based
4-OHT prodrug can achieve acceptable in vivo efficacy
in an ERα + breast cancer xenograft model as compared
to tamoxifen in a dose dependent manner. Pharmacoki-
netic studies were performed in mice to investigate the
metabolism, distribution, and concentration change
over time after a single dose of ZB497, in comparison
with tamoxifen and 4-OHT. Moreover, tumor tissues
from mice were analyzed for drug accumulation after
21 days of treatment of ZB497 or tamoxifen.
Methods
Reagents and materials
All reagents, solvents, and analytical standards were
purchased from Sigma Aldrich (St. Louis, MO) and
Fisher Scientific (Fairfield, NJ). ZB497 were synthesized
following the synthetic route described in detail in a
previous report [21].
In vivo efficacy study in mice
Four- to six-week old female ovariectomized Nu/Nu
mice were purchased from Charles River Laboratories
(Wilmington, MA). The mice were given a period of
adaptation in a sterile and pathogen-free environment
with phytoestrogen-free food and water ad libitum.
MCF-7 cell line was purchased from ATCC (ATCC
#HTB-22, Manassas, VA), and routinely cultured in
phenol red-free DMEM medium supplemented with
5 % FBS, 4 mM glutamine, 1 mM sodium pyruvate,
100 IU/mL penicillin, 100 μg/mL streptomycin and
0.25 μg/mL amphotericin. The cells were harvested in
the exponential growth phase using a PBS/EDTA solu-
tion. The animals were injected bilaterally in the mam-
mary fat pad (MFP) with 5 × 106 viable cells suspended
in 50 μL sterile PBS mixed with 100 μL Matrigel (re-
duced growth factor; BD Biosciences, Bedford, MA).
17β- estradiol pellets (0.72 mg, 60-day release; Innova-
tive Research of America, Sarasota, FL) were implanted
subcutaneously in the lateral area of the neck using a
precision trochar (10 gauge) at the time of cell injec-
tion. All procedures in animals were carried out under
anesthesia using a mixture of isofluorane and oxygen
delivered by mask. Tumors were allowed to form and
at day 15 post cell injection mice were randomized into
groups of 5 mice each. Mice were treated daily with
intraperitoneal (i.p.) injection or oral gavage of either
vehicle (1:20 DMSO/PBS for i.p. or 1:10 ethanol/PBS
for oral gavage) or a drug for 21 days. For the dose-
dependent efficacy study, five groups (5 mice/group) of
tumor-bearing nude mice (one control and one group
each per dose per drug). Tumor size was measured 3
times weekly using digital calipers. Tumors were surgi-
cally removed from sacrificed mice treated with a daily
dose of either 1 mg/kg tamoxifen or 1 mg/kg ZB497 by
oral gavage for 7 days, weighed, and stored at −80 °C
until sample preparation and analysis.
Pharmacokinetic studies
Female C57BL/6 mice were used for the pharmacoki-
netic study of ZB497. For intraperitoneal administra-
tion of drugs, mice were injected with PBS containing
ZB497, tamoxifen, or 4-OHT by adding appropriate
amounts of individual stock solutions of the drugs
dissolved in DMSO. For oral administration, mice were
given oral gavage containing PBS and ethanol-dissolved
ZB497, 4-OHT, or tamoxifen at a single dose of 1 mg/
kg/mouse. After i.p or oral administration, blood sam-
ples were collected from the orbital sinus of the mice
at various time points with each group of mice sub-
jected to only one sampling. Mice blood was collected
with a capillary into 1.5 mL microcentrifuge tubes contain-
ing 0.1 mL of 10 % EDTA anticoagulant. Plasma was then
separated from red cells by centrifugation in a refrigerated
centrifuge at 4 °C and transferred to a separate tube. The
plasma samples were frozen at −80 °C until analysis.
Analysis of drug concentrations in plasma and tumor tissues
Plasma samples were extracted with chloroform:metha-
nol (2:1) using traditional Folch method for lipid extrac-
tion. Methanol (1 mL) and chloroform (2 mL) were
added to each plasma sample followed by addition of
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5 ng trans-Tamoxifen-13C2, 15 N to each sample as the
internal standard. The mixtures were stored at −20 °C
overnight. Next, the samples were sonicated for 5 min
and centrifuged with a Thermo Scientific Heraeus Mega-
fuge16 Centrifuge. The top layer was transferred to an-
other test tube. The bottom layer was washed with
1 mL chloroform:methanol (2:1), centrifuged, and the
top layer was transferred and combined with the previ-
ous top layer. Eight tenth of a milliliter HPLC grade
water was added to the extracts. After vortexing, the
mixture was centrifuged. The bottom layer was dried
out with nitrogen and re-suspended in 100 μL HPLC
grade acetonitrile. An aliquot of 10 μL sample was
injected onto a Hypersil Gold column (50 × 2.1 mm;
particle size 1.9 μm, Thermo Scientific) on a Dionex
Ultimate 3000 UPLC system equipped with a TSQ
Vantage triple quadrupole mass spectrometer for ana-
lysis. A binary mobile phase (A: water with 0.05 % for-
mic acid; B: acetonitrile with 0.05 % formic acid) was
used to achieve a gradient of initial 30 % B for 1 min
and then to 80 % B at 8 min, to 100 % B at 9 min, and
returned to 30 % B for 4 min. The flow rate was
controlled at 0.6 mL/min. The settings of HESI source
were as follows: spray voltage (3200 volt); vaporizer
temperature (365 °C); sheath gas pressure (45 psi); auxil-
iary gas pressure (10 psi); capillary temperature (330 °C).
Nitrogen was used as the sheath gas and auxillary gas.
Argon was used as the collision gas.
For determination of drug concentrations in tumor tis-
sues, tumors were initially homogenized in 3 mL chloro-
form:methanol (2:1 v:v) with a PYREX™ Tenbroeck
tissue grinder. The same solvent (1 mL) was used to
wash the tissue grinder three times and the washings
were combined with the initial homogenized tumor sus-
pension. After adding 5 ng trans-tamoxifen-13C2, 15 N to
each sample as an internal standard, the mixtures were
stored at −20 °C overnight. The mixtures were then son-
icated for 5 min and centrifuged. The top layer was
transferred to another test tube. The bottom layer was
washed with 1 mL chloroform:methanol (2:1), centri-
fuged, and the top layer from this wash was transferred
and combined with the previous top layer. After adding
water (1.4 mL) to the extract, vortexing and centrifuging,
and the bottom layer was dried out with nitrogen and
re-suspended in 100 μL HPLC grade acetonitrile for ana-
lysis on the HPLC-TSQ instrument under the same con-
ditions as those used for the analysis of the plasma
samples.
Ethical considerations and statistical analysis
All procedures involving the animals were conducted
in compliance with State and Federal laws, standards
of the U.S. Department of Health and Human Services,
and guidelines established by the Institutional Animal
Care and Use Committee at Xavier University. All ani-
mal experiments were approved by Xavier’s Institu-
tional Animal Care and Use Committee. The facilities
and laboratory animals program of Xavier University
are accredited by the Association for the Assessment
and Accreditation of Laboratory Animal Care. Statis-
tical analyses were performed using Microsoft excel
software. Pharmacokinetic data analyses were per-
formed using the PKsoftware [22].
Results
The boronic prodrug ZB497 is effective in the inhibition
of xenograft tumor growth in mice
We have previously shown that boron-based 4-
hydroxytamoxifen prodrugs are active antiestrogenic
agents in vitro, with potencies exceeding that of tam-
oxifen in MCF-7 and T47D breast cancer cells the ex-
press ERα [21]. To determine if these in vitro activities
translate to in vivo efficacy, we utilized a nude mouse
model in which MCF-7 cells were injected bilaterally
into the mammary fat pad (MFP) to form tumor xeno-
grafts. Mice were treated daily with intraperitoneal
(i.p.) injections of either vehicle (1:5 DMSO/PBS),
tamoxifen (1.0 mg/kg), 4-OHT (1.0 mg/kg), or ZB497
(1.0 mg/kg) for 21 days. As shown in Fig. 1, i.p. ad-
ministered ZB497 was found to inhibit tumor growth
in mice as effectively as either tamoxifen or 4-OHT.
While statistically insignificant, ZB497 showed a slightly
greater degree of efficacy than tamoxifen and 4-OHT
treatments.
Metabolism and pharmacokinetics of ZB497
As demonstrated in our previous study on breast can-
cer cells [21], ZB497 was rapidly converted to the
boronic acid form of the prodrug before being further
transformed to 4-hydroxytamoxifen. To investigate how
the prodrug is metabolized and distributed in mice, we
measured plasma concentrations of the prodrug and its
metabolites over a course of 7 days upon a single dose
by either i.p. injection or oral gavage. As illustrated in
Fig. 2, a total of 8 metabolic products of ZB497 were
identified through the analysis of mouse plasma. ZB497
is first hydrolyzed to B415, the boronic acid, followed
by a facile conversion to 4-OHT (70–80 %) and endoxi-
fen (5–20 %), two active metabolites of tamoxifen. The
predominant biotransformation route is an oxidative
deboronation catalyzed by P450 enzymes in the pres-
ence of reactive oxygen species (ROS) [23]. For example,
the presence of hydrogen peroxide may contribute to the
oxidative cleavage of the boron-aryl carbon bond. Several
minor metabolites make up approximately 1–3 % of the
total, including B401 (1-2 %), a precursor of endoxifen
and product of demethylation of B415, B417 (<1 %), a
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product of hydroxylation of B401, and B413A, B413B, and
B413C (<1 % total), isomeric mixture of metabolites
resulting from hydroxylation of B415.
To determine drug concentrations in mouse plasma,
B497, 4-OHT, or tamoxifen were dissolved in DMSO,
diluted in PBS, and injected intraperitoneally into the
mice at a single dose of 1 mg/kg. Blood samples were
then taken from mice at various time intervals for ana-
lysis of drugs and related compounds by UPLC-MS/MS.
The results are summarized in Fig. 3a-c. In the case of
tamoxifen i.p. administration, the peak concentration of
tamoxifen and 4-OHT were observed in the 6-h blood
samples at 50 ng/mL and 45 ng/mL, respectively. Both
tamoxifen and 4-OHT concentrations decreased rapidly
Fig. 1 Inhibition of xenograft tumor growth by i.p. administered tamoxifen, 4-OHT, or ZB497. Mice were treated daily with intraperitoneal (i.p.)










































Fig. 2 Structures of identified ZB497 metabolic products in mouse blood. A total of eight metabolic products were identified by HPLC-tandem
mass spectrometry with approximate range of relative quantities indicated for each structure
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to non-detectable levels on Day 3 (72 h, Fig. 3a). In mice
injected with 4-OHT, the only detected and quantifiable
compound in blood was 4-OHT (Fig. 3b) which varied
from 47 ng/mL at 24 h to below detection limit at 72 h.
At the same dose, however, ZB497 resulted in a peak
concentration of over 1600 ng/mL, nearly 40-fold in-
crease in plasma concentration of 4-OHT over the ad-
ministration of 4-OHT or tamoxifen (Fig. 3c). These
results were at once encouraging and surprising. The in
vivo PK data not only confirmed the hypothesis that the
boronic prodrug can be efficiently converted to 4-OHT,
the desired active form of the drug, in animals, but also
far exceeded our expectation in terms of vastly improved
bioavailability, namely, a 40-fold increase of peak plasma
concentrations of 4-OHT.
Mindful of the potential clinical applications for
ZB497, we next examined the pharmacokinetics of the
boron prodrug when orally administered to mice. In
this experiment, mice were given oral gavage contain-
ing PBS and ethanol-dissolved tamoxifen, 4-OHT, or
ZB497, at a single dose of 1 mg/kg. Blood samples were
taken from mice at various time points ranging from
2 h to 7 days after the single dose. As shown in Fig. 3d,
a single oral dose of tamoxifen resulted in a peak tam-
oxifen and 4-OHT concentration of 2.8 and 0.8 ng/mL,
respectively, both reached at 2 h. In mice given 4-OHT,
the peak concentration of 4-OHT after its oral
administration was reached at 2 h at 3.6 ng/mL, but
rapidly decreased to below 0.4 ng/mL after 6 h (Fig. 3e).
In contrast, when mice were orally administered with
ZB497 (Fig. 3f ), the peak 4-OHT concentration reached
a high level of 114 ng/mL, a value that is 32 times
higher than in 4-OHT administration, and over 140
times higher than the 4-OHT concentration from tam-
oxifen administration. Thus, oral administration of
ZB497 also afforded a dramatically increased 4-OHT
level in systemic circulation.
The pharmacokinetic parameters were calculated using
an excel-based PK software [22] to obtain the t1/2 and area
under curve (AUC) values for all three drugs. As shown in
Fig. 3 Pharmacokinetics of tamoxifen, 4-hydroxytamoxifen, and ZB497 in mice after i.p. administration (a-c), or oral administration (d-f) at a single
dose of 1 mg/kg. For i.p. administration of drugs, mice were injected with PBS containing ZB497, tamoxifen, or 4-OHT by adding appropriate
amounts of individual stock solutions of the drugs dissolved in DMSO. For oral administration, mice were given oral gavage containing PBS and
ethanol-dissolved ZB497, tamoxifen, or 4-OHT
Table 1 Pharmacokinetic parameters for tamoxifen, 4-OHT, and







tmax (hrs) 2 (Tam) 2 (4-OHT) 2 (4-OHT)
2 (4-OHT) 2 (Endoxifen) 6 (Endoxifen)
t1/2 (hrs) 32.5 (Tam) 31.7 (4-OHT) 39.5 (4-OHT)
22.6 (4-OHT) 19.5 (Endoxifen) 36.5 (Endoxifen)
Cmax (ng/mL) 2.78 (Tam) 3.6 (4-OHT) 114.0 (4-OHT)
0.80 (4-OHT) 5.9 (Endoxifen) 14.4 (Endoxifen)
AUC (ng/mL*h) 160.6 (Tam) 61.5 (4-OHT) 3777.7 (4-OHT)
21.3 (4-OHT) 61.2 (Endoxifen) 767.4 (Endoxifen)
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Table 1, tamoxifen afforded an AUC of 160.6 ng/mL*h for
tamoxifen and 21.3 ng/mL*h for 4-OHT, compared to
61.5 for 4-OHT in mice given oral gavage of 4-OHT
directly. While tamoxifen administration did not yield
quantifiable endoxifen levels, 4-OHT orally given to mice
generated an endoxifen concentration comparable to 4-
OHT, with an AUC value of 61.2 ng/mL*h. With ZB497
administration, both 4-OHT and endoxifen were mea-
sured at dramatically higher levels in plasma with AUC
values reaching 3777.7 ng/mL*h for 4-OHT, and 767.4 ng/
mL*h for endoxifen. It is well known that tamoxifen me-
tabolism in mice differs significantly from that in humans in
terms of the plasma level of 4-hydroxytamoxifen and endoxi-
fen. In mice treated with tamoxifen, the relative concentra-
tion of 4-OHT is much higher than that detected in humans
whereas the endoxifen level is lower than in humans [23].
Thus, the ratio of 4-OHT from ZB497 to that from tamoxi-
fen may not reflect what might be observed in humans.
ZB497 is more effective than tamoxifen at lowered dose
It would follow that such dramatic enhancement in
plasma concentration of an active drug must have
therapeutic consequences. To investigate the effects of
increased bioavaibility of 4-OHT enabled by the pro-
drug ZB497 on therapeutic efficacy, mice bearing MCF-
7 xenograft tumors were given either tamoxifen or
ZB497 at two oral dose levels, 1 mg/kg and 0.1 mg/kg
(Fig. 4). At the higher dose of 1 mg/kg, ZB497 exhibited
slightly better efficacy than tamoxifen in inhibiting
tumor growth, albeit not statistically significant at earl-
ier data points. Still, on day 31, 1 mg/kg of ZB497
group had an average tumor size of 1982 mm3, com-
pared to the 1 mg/kg tamoxifen group which had an
average tumor size of 2829 mm3. When the oral dose
was lowered to 0.1 mg/kg, the mice group given tam-
oxifen showed significantly decreased efficacy in tumor
growth inhibition, with the average tumor size reaching
4205 mm3 at end of treatment (p < 0.05 compared to
1 mg/kg tamoxifen treatment). In contrast, ZB497 at
0.1 mg/kg dose remained at least as effective as a 10-
times higher dose of tamoxifen (1 mg/kg) with the final
average tumor size measured at 2364 mm3 (p < 0.05
compared to 0.1 mg/kg tamoxifen treatment). This
finding provided crucial evidence that the enhanced
plasma drug level afforded by ZB497 can be translated
to increased therapeutic efficacy.
ZB497 treatment resulted in higher drug concentrations
in tumor
As a cancer treatment regimen, relatively high drug
concentration in tumor tissue compared to non-target
tissues is advantageous for many reasons, including en-
hanced efficacy and reduced side effects. When com-
pared to tamoxifen, ZB497 and related metabolites were
found to have significantly higher concentrations in
mouse blood, which may be the main reason why ZB497
remained therapeutically effective at lower doses than
tamoxifen. To determine if indeed higher blood concen-
tration of the drug and its metabolites results in enrich-
ment in tumor tissues, we analyzed xenograft tumor
tissues for all measurable drug concentrations.
Tumor samples were analyzed for tamoxifen, desmethyl-
tamoxifen (DMT), 4-hydroxytamoxifen, endoxifen, and all
boron-containing forms of the drug. Figure 5 shows the
concentration of each of these drug forms measured in ex-
cised tumors. In tumors from tamoxifen-treated mice, the
Fig. 4 Dose-dependent inhibition of tumor growth in mice that were given oral gavage of vehicle, tamoxifen, or ZB497 at two different doses.
Five groups (5 mice/group) of mice bearing MCF-7 xenograft tumors were treated daily with oral gavage of either vehicle (1:10
ethanol/PBS) or a drug at 0.1 mg/kg or 1 mg/kg for 21 days
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average concentration of tamoxifen, 4-OHT, DMT,
and endoxifen were 4.77, 11.30, 0.26 and 0.4 ng/g, re-
spectively, with the total drug concentration in tumor
tissues reaching 16.74 ng/g. In ZB497-treated mice, the
most abundant drug form was 4-OHT at 41.32 ng/g,
nearly 4 times higher than in the tamoxifen-treated group.
Endoxifen level in ZB497-treated mice was measured at 2.
61 ng/g, a 6-fold increase compared to the tamoxifen-
treated mice. Moreover, B415, the boronic acid form of
the prodrug ZB497 reached 39.01 ng/g and the demethy-
lated boronic acid (B401) was measured to be 31.80 ng/g,
in contrast to the metabolite distribution in mouse blood,
where the boron-containing drug forms were significantly
less abundant. The total concentration of all quantifi-
able drugs after repeated tamoxifen doses is 16.74 ng/
g, whereas the total drug concentration resulting from
repeated ZB497 doses at 1 mg/kg reached 114.74 ng/g,
demonstrating the superior overall bioavailability of
the boronic prodrug of 4-OHT in tumor. Importantly,
as evidenced in the previous in vitro pharmacology
study [21], the boronic prodrug forms, including B415,
are also potent antiestrogenic agents, thus the accu-
mulation of the boronic prodrug forms in tumor can
have two-fold benefits for hormone therapy. First, they
contribute to the overall active drug concentration in
tumor cells. Second, they serve as a reservoir to continu-
ously release the active tamoxifen metabolites, 4-OHT and
endoxifen as a result of oxidative deboronation in situ, by
reactive oxygen species such as hydrogen peroxide within
tumor cells.
Discussion
Tamoxifen is a prodrug and its full therapeutic effect
depends on the biotransformation of tamoxifen into its
active metabolites, 4-OHT and endoxifen. Thus the use
of 4-OHT as an agent for endocrine therapy is attractive
in that not only it is 100-fold more potent as an anties-
trogen than tamoxifen but also 4-OHT has well-known
pharmacological and toxicological profiles. It can cir-
cumvent the problem associated with deficient CYP2D6
metabolism and potentially lower the dosage require-
ment owing to its inherent high potency. The problem
lies in 4-OHT’s rapid first-pass metabolism, and the poor
bioavailability of 4-OHT when used directly via oral
administration.
By introducing a cleavable boron-aryl carbon bond to
replace the hydroxyl group in 4-OHT, we have designed
and tested a boronic prodrug, ZB497 for its ability to
overcome the poor bioavailability of 4-OHT. Our study
has demonstrated that ZB497 can not only effectively
deliver the desired form of the drug, 4-OHT in an ani-
mal model, but also at a much higher plasma concentra-
tion. The facile oxidative deboronation of the prodrug
under physiological conditions is likely facilitated by the
presence of P450 enzymes and/or reactive oxygen spe-
cies [24]. In mouse blood after oral or intraperitoneal
administration of ZB497, the predominant drug form is
4-OHT, constituting about 75-85 % of total drug con-
centration in blood. In addition, compared to tamoxifen
or 4-OHT treatment, ZB497 also afforded higher levels
of endoxifen in plasma, independent of CYP2D6 status.
Such guaranteed delivery of 4-OHT can effectively over-
come differences in therapeutic efficacy due to variations
in patient metabolism.
But more importantly, the boronic prodrug yielded
an astonishingly higher concentration of 4-OHT in
systemic circulation than was expected, lending itself
to an equally enhanced bioavailability that would have
favorable clinical implications. The 30- to 40-fold in-












































Drug Concentrations in Xenograft Tumor
Tamoxifen Treatment
ZB497 Treatment
Fig. 5 Comparison of individual and total drug and metabolite concentrations in tumor tissues from mice treated with ZB497 or tamoxifen.
Tamoxifen, 4-OHT, and desmethyltamoxifen (DMT) were detected and quantified in tumor tissues from tamoxifen treated mice. In tumor tissues
from ZB497-treated mice, 4-OHT, endoxifen, B401 and B415 were detected and quantified
Zhong et al. BMC Cancer  (2015) 15:625 Page 7 of 9
oral administration of ZB497, compared to 4-OHT ad-
ministration at equal dosage, strongly suggests that the
boronic structure does more than just delivering the
desired 4-OHT form while preventing its rapid clear-
ance from the body via glucuronidation. Through a
mechanism not yet fully accounted for, the boronic
structure must be responsible for enabling the remark-
able enrichment in plasma concentration of 4-OHT as
measured in our pharmacokinetic studies. From the
metabolism data both in vitro [21] and in vivo in the
current study, we know that the predominant form of
ZB497 is B415, the boronic acid form of the prodrug.
It is well known that boronic acids can form reversible
complexes with 1,2 and 1,3 diol groups common in
sugar molecules and glycoproteins [25, 26], which
upon hydration would release the boronic acids. We
hypothesize that such reversible, covalent complexes
between boronic acid and a diol group may facilitate
the enrichment in plasma due to the abundance of
molecules containing the diol groups. Moreover, such
complexes may serve as a reservoir to release the bo-
ronic acid as the prodrug undergoes deboronation to
be converted to 4-OHT. Indeed, this unique property
of boronic acid has recently been exploited for an
enhanced delivery of insulin for treatment of diabetes
[27]. Consequently, in addition to markedly greater
plasma concentration, the clearance time of 4-OHT from
ZB497 (t1/2 = 39.5 hrs) is significantly prolonged compared
to direct administration of 4-OHT (t1/2 = 31.7 h) or tam-
oxifen (t1/2 for 4-OHT = 22.6 h).
As an immediate result of increased plasma 4-OHT
concentration, we found that xenograft tumor tissues
also have significantly higher drug accumulation. We
also noted that in tumor tissues, the percentage of
boron-containing drugs was significantly higher than
in plasma after repeated doses of ZB497, suggesting a
preferential uptake of the boronic acid form of the pro-
drug by cancer cells. Nevertheless, 4-OHT concentration
in tumor tissues from ZB497-treated mice was still 4 times
higher than found in mice treated with tamoxifen.
We believe that enhanced overall bioavailability of
4-OHT conferred by ZB497, as evidenced in the over
30 fold increase in peak plasma concentration and the
8-fold increase in total drug accumulation in tumor
tissues culminated in ZB497’s superior in vivo efficacy.
At the dosage lowered to 1/10 of a milligram per kilo-
gram, ZB497 remained therapeutically effective in
inhibiting xenograft tumor growth, whereas tamoxifen
largely lost its efficacy for tumor inhibition at this
dose. On the other hand, at the higher dosage of 1 mg/kg,
the efficacy difference between ZB497 and tamoxifen was
not as prominent. In addition, the degree of tumor growth
inhibition by ZB497 at two doses was also similar, and not
proportional to the 10-fold difference in dosage. We
speculate that the maximum therapeutically effective
drug concentration in systemic circulation may have
been reached by ZB497 at 0.1 mg/kg and by tamoxifen
at 1 mg/kg. Thus, further increasing the dosage of ZB497
to 1 mg/kg may not lead to proportional increase in effi-
cacy in mice.
As demonstrated in the efficient metabolic conversion
of ZB497 to 4-hydroxytamoxifen in mice, the prodrug
aims to deliver a therapeutically effective dose of the
active drug form, 4-OHT. Therefore, it is conceivable
that the main possible side effects of the prodrug would
be associated with 4-OHT, which is a SERM that be-
haves similarly as tamoxifen with up to 100-fold greater
potency than tamoxifen. It is unknown if 4-OHT may
exert 100-fold greater side effects if given at the same
dose, but at a fraction of the dose that may be required
to reach a therapeutic level, the side effects may not
exceed those of tamoxifen. Moreover, because use of
ZB497 will eliminate tamoxifen and other related metab-
olites in systemic circulation, side effects due to these
substances may also be eliminated.
Each dose of one mg of ZB497 will generate 0.23 mg
of pinacol and 0.12 mg of boric acid. At these low levels,
both pinacol and boric acid are not known to be toxic to
humans. The LD50 of pinacol in mouse is 3,380 mg/kg
oral dose [28] and the LD50 of boric acid in rat is
2660 mg/kg [29]. Notably, the mean daily intakes of
boron from food and beverages alone for male and
female adults are 1.28 and 1.00 mg respectively [30].
These data suggest that side effects due to the boronic
structure of ZB497 may be minimal to nonexistent.
Conclusions
We have discovered that the boronic prodrug of 4-
OHT offers potential solutions to two clinical problems
facing tamoxifen therapy. First, patients with deficient
CYP2D6 enzymatic function due to genetic polymorph-
ism or due to drug-drug or drug-supplement inter-
action may not benefit fully from tamoxifen therapy.
ZB497 has been shown to deliver the active ingredient,
4-OHT to the systemic circulation in an animal model.
Second, persistent side effects such as hot flashes have
contributed to low patient compliance with long-term
treatment regimens, raising the risk of cancer recur-
rence. ZB497 is shown to have a unique advantage in
that it can reach therapeutically effective concentration
of 4-OHT at a fraction of the dose that would be
required if tamoxifen or 4-OHT is administered. Lower
dosage in the clinic could translate to reduced side ef-
fects, potentially increasing patient compliance and
lower the risk of cancer recurrence.
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